(c) 2024 PillSync.com

Ranitidine 150 MG Oral Tablet

INDICATIONS AND USAGE Ranitidine Tablets is indicated in Short- term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of Ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo – controlled comparative studies have been carried out for periods longer than 1 year. The treatment of pathological hypersecretory conditions. (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with Ranitidine Tablets USP, 150 mg twice daily. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with Ranitidine Tablets USP, 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis.

VKT Pharma Private Limited


4 years ago ROUND ORANGE V 02 Ranitidine 150 MG Oral Tablet

ROUND ORANGE V 02

HOW SUPPLIED Ranitidine Tablets USP, 150 mg (Ranitidine HCl equivalent to 150 mg of ranitidine) are orange, film-coated, round shaped tablets debossed with 'V' on one side and '02' on the other side. They are available in following counts Bottles of 500 (NDC 71821-001-01) tablets Ranitidine Tablets USP, 300 mg (Ranitidine HCl equivalent to 300 mg of ranitidine) are yellow, film-coated, oval shaped tablets debossed with 'V' on one side and '03' on the other side. They are available in following counts Bottles of 250 (NDC 71821-002-01) tablets Store between 15º and 30ºC (59º and 86ºF) in a dry place. Protect from light. Replace cap securely after each opening. Contains color additives including FD&C yellow No.5 (tartrazine) MULTISTIX is a registered trademark of Bayer Healthcare LLC. VKT Pharma Private Limited Survey No.21-27, Derasam Village Srikakulam District, Andhra Pradesh India-532409 February 2018


More pills like ROUND V 02

Related Pills

Ranitidine 300 MG Oral Tablet

VKT Pharma Private Limited












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site